GlobeNewswire
Stryker declares an $0.88 per share quarterly dividend
📈
AI Sentiment
Highly Positive
8/10
- Home
- SYK
as of 12-12-2025 1:40pm EST
$352.72
$0.25
-0.07%
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Chart Type:
Time Range:
| Founded: | 1941 | Country: | United States |
| Employees: | N/A | City: | PORTAGE |
| Market Cap: | 141.2B | IPO Year: | N/A |
| Target Price: | $432.14 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 7.61 | EPS Growth: | -18.39 |
| 52 Week Low/High: | $329.16 - $406.19 | Next Earning Date: | 01-27-2026 |
| Revenue: | $24,381,000,000 | Revenue Growth: | 10.95% |
| Revenue Growth (this year): | 12.01% | Revenue Growth (next year): | 8.59% |
AI-Powered SYK Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 68.00%
68.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Stryker Corporation (SYK)
Wells Preston Wendell
Sell
VP, Chief Financial Officer
SYK Nov 20, 2025
Avg Cost/Share
$365.88
Shares
165
Total Value
$60,370.20
Owned After
6,694
SEC Form 4
Berry William E Jr
Sell
VP, Chief Accounting Officer
SYK Nov 14, 2025
Avg Cost/Share
$365.49
Shares
1,953
Total Value
$713,801.97
Owned After
2,833
SEC Form 4
STRYKER RONDA E
Sell
Director
SYK Nov 6, 2025
Avg Cost/Share
$353.13
Shares
276,173
Total Value
$97,565,693.64
Owned After
2,977,885
STRYKER RONDA E
Sell
Director
SYK Nov 5, 2025
Avg Cost/Share
$356.95
Shares
243,827
Total Value
$87,040,447.25
Owned After
2,977,885
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Wells Preston Wendell | SYK | VP, Chief Financial Officer | Nov 20, 2025 | Sell | $365.88 | 165 | $60,370.20 | 6,694 | |
| Berry William E Jr | SYK | VP, Chief Accounting Officer | Nov 14, 2025 | Sell | $365.49 | 1,953 | $713,801.97 | 2,833 | |
| STRYKER RONDA E | SYK | Director | Nov 6, 2025 | Sell | $353.13 | 276,173 | $97,565,693.64 | 2,977,885 | |
| STRYKER RONDA E | SYK | Director | Nov 5, 2025 | Sell | $356.95 | 243,827 | $87,040,447.25 | 2,977,885 |
Latest Stryker Corporation News
SYK Breaking Stock News: Dive into SYK Ticker-Specific Updates for Smart Investing
MT Newswires
Citigroup Adjusts Stryker Price Target to $420 From $455, Maintains Buy Rating
📊
AI Sentiment
Positive
6/10
Simply Wall St.
Stryker (SYK) Leadership Shake-Up: Evaluating the Stock’s Valuation After New President and COO Appointment
📊
AI Sentiment
Positive
6/10
Zacks
ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?
📈
AI Sentiment
Highly Positive
9/10
Insider Monkey
Stryker (SYK) Shows ‘Muscle’ at Investor Day, but Truist Stays Neutral
📊
AI Sentiment
Positive
7/10
MedTech Dive
Olympus-backed Swan EndoSurgical names Erik Todd as CEO
📈
AI Sentiment
Highly Positive
8/10
Compare SYK vs Leading Stocks
See how SYK stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SYK Stryker Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.